Trexquant Investment’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-205,219
| Closed | -$8.26M | – | 1876 |
|
|
2026
Q1 | $8.26M | Buy |
205,219
+10,627
| +5% | +$229K | 0.06% | 446 |
|
|
2025
Q4 | $4.89M | Sell |
194,592
-392,347
| -67% | -$9.21M | 0.04% | 603 |
|
|
2025
Q3 | $13.3M | Buy |
586,939
+259,518
| +79% | +$6.05M | 0.14% | 174 |
|
|
2025
Q2 | $5.67M | Sell |
327,421
-57,501
| -15% | -$1.06M | 0.06% | 484 |
|
|
2025
Q1 | $8.42M | Buy |
384,922
+181,914
| +90% | +$5.03M | 0.1% | 316 |
|
|
2024
Q4 | $6.48M | Buy |
+203,008
| New | +$6.1M | 0.08% | 424 |
|
|
2024
Q3 | – | Sell |
-149,160
| Closed | -$5.72M | – | 1514 |
|
|
2024
Q2 | $5.72M | Buy |
+149,160
| New | +$6.76M | 0.09% | 365 |
|
|
2023
Q3 | – | Sell |
-51,988
| Closed | -$4.74M | – | 1436 |
|
|
2023
Q2 | $4.74M | Buy |
+51,988
| New | +$4.49M | 0.12% | 223 |
|
|
2022
Q3 | – | Sell |
-9,750
| Closed | -$441K | – | 1339 |
|
|
2022
Q2 | $441K | Buy |
+9,750
| New | +$445K | 0.02% | 900 |
|
|
2021
Q3 | – | Sell |
-10,262
| Closed | -$649K | – | 1112 |
|
|
2021
Q2 | $649K | Buy |
10,262
+5,212
| +103% | +$269K | 0.05% | 405 |
|
|
2021
Q1 | $217K | Buy |
+5,050
| New | +$239K | 0.02% | 926 |
|
|
2020
Q3 | – | Sell |
-17,189
| Closed | -$561K | – | 1179 |
|
|
2020
Q2 | $561K | Buy |
17,189
+8,559
| +99% | +$275K | 0.04% | 634 |
|
|
2020
Q1 | $231K | Buy |
+8,630
| New | +$306K | 0.02% | 936 |
|
Other funds holding APLS
Trexquant Investment's APLS Position: Q2 2026 in Review
Trexquant Investment sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 205,219 shares — an estimated $8.26M sold.
Trexquant Investment first reported a position in APLS in Q1 2020 and held it in 13 quarters. The position peaked at $13.3M in Q3 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Trexquant Investment reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Trexquant Investment sold 205,219 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.26M.
- Trexquant Investment first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 13 quarters.
- Trexquant Investment's Apellis Pharmaceuticals position peaked at $13.3M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.